Vanguard Capital reports 7.49% stake in Bristol-Myers Squibb (BMY)
Rhea-AI Filing Summary
Bristol-Myers Squibb Co reported that Vanguard Capital Management beneficially owned 153,108,018 shares of common stock, representing 7.49% of the class as of 03/31/2026. The filing lists sole dispositive power for 153,108,018 shares and sole voting power for 20,787,778 shares. The Schedule 13G was signed on 04/29/2026 by Ashley Grim.
Positive
- None.
Negative
- None.
Insights
Vanguard holds a sizable passive stake in BMY (7.49%).
Vanguard Capital Management reports beneficial ownership of 153,108,018 shares of Bristol-Myers Squibb common stock, representing 7.49% of the class as of 03/31/2026. The filing shows dispositive control across those shares, which typically signals portfolio-level exposure rather than a change in control intent.
Future filings may show adjustments; shareholder voting influence is limited to the 20,787,778 shares for which Vanguard reports sole voting power.
Schedule 13G disclosure aligns with passive investor reporting requirements.
The filing follows Schedule 13G conventions, identifying beneficial ownership, voting power, and dispositive power. It includes the SEC release citation describing aggregation rules for Vanguard-affiliated entities. Filing was executed and signed on 04/29/2026, meeting signature requirements.
Stakeholders should watch for any future amendments if Vanguard's status or ownership percentage changes above reporting thresholds.
Key Figures
Key Terms
Beneficially owned regulatory
Sole dispositive power regulatory
Schedule 13G regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.